This is a prospective, open-label, single arm, non-randomized study of CPI-200 in patients with advanced tumors. CPI-200 is administered via intravenous infusion using an accelerated titration method followed by a conventional 3 + 3 study design to identify the maximum tolerated dose (MTD)
Primary Objectives: • To determine the safety, tolerability and maximum tolerated dose (MTD) of CPI-200 in patients with advanced tumors Secondary Objectives: * To evaluate the pharmacokinetics (PK) of CPI-200 * To evaluate clinical response and resolution of symptoms after CPI-200 treatment * To characterize adverse events of CPI-200 in patients with advanced cancers Up to 7 dose levels of CPI-200 will be tested using an accelerated titration method followed by a conventional 3 + 3 dose escalation study design. MTD will be defined as the dose associated with a dose limiting toxicity (DLT) in less than or equal to 33% of patients at the dose level tested. Dose limiting toxicity (DLT) is defined as one of the following events occurring from the intravenous injection of CPI-200 within 21 days: * All Grade 4 or greater adverse events as determined by CTCAEv5 criteria, excluding toxicities clearly related to disease progression or inter-current illness * Any Grade 3 or greater non-hematologic, non-dermatologic toxicity with the exception of Grade 3 nausea, vomiting or diarrhea if lasting less than 72 hours, alopecia, or Grade 3 fatigue if lasting less than 7 days as determined by CTCAEv5 criteria * Grade 3 thrombocytopenia in the presence of bleeding * Grade 3 or greater febrile neutropenia * Any hematologic or non-hematologic adverse events or abnormal laboratory value(s) related to CPI-200 that result(s) in permanent study discontinuation of study treatment
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
17
CPI-200 will be administered via intravenous infusion on Day 1 of a 21-Day cycle
South Texas Accelerated Research Therapeutics (START Midwest)
Grand Rapids, Michigan, United States
Maximum Tolerated Dose (MTD)
• To determine the maximum tolerated dose (MTD), which is defined as the dose level at which fewer than 33% of patients experience a dose limiting toxicity (DLT) using a 3+3 strategy as assessed by CTCAE
Time frame: 21 days
Rate of Clinical Benefit
• To assess clinical benefit by response rate and resolution of symptoms, which will be reported as response rate (%) of participants
Time frame: through study completion, an average of 4 months
Rate of Adverse Effect
• To assess adverse effect as either treatment-related or non-treatment-related as defined by CTCAE, which will be reported as % of participants
Time frame: through study completion, an average of 4 months
Maximum Plasma Concentration (Cmax)
• To evaluate maximum plasma concentration (Cmax) of CPI-200 in patients tested
Time frame: 8 Days
Area Under the Curve (AUC)
• To evaluate area under the curve (AUC) of CPI-200 in patients tested
Time frame: 8 Days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.